Up to 25,000 people with ulcerative colitis (UC) in England could be in line for treatment with Pfizer’s once-daily oral therapy Velsipity, after NICE recommended its use
Fresh from the $43 billion acquisition of antibody-drug conjugate (ADC) specialist Seagen, Pfizer has laid out plans for its dedicated oncology division in front of invest
Regeneron’s bid to join the market for BCMA-targeted bispecific antibodies for multiple myeloma is nearing a conclusion, with the FDA starting a priority review of its lin
Pfizer’s JAK/TEC inhibitor Litfulo has been recommended for NHS use as a treatment for hair loss caused by severe alopecia areata, the first drug therapy for a condition t
The European Commission has approved Pfizer’s S1P receptor modulator Velsipity as a treatment for ulcerative colitis (UC), raising the pressure on Bristol-Myers Squibb’s f
People in Great Britain will be able to buy the latest Omicron-directed version of Pfizer/BioNTech’s COVID-19 vaccine from retail pharmacies, starting in March.
An alliance between Johnson & Johnson and tech giant NVIDIA aims to bring artificial intelligence into operating rooms, assisting surgeons even as they wield their sca
Today, pharma brand planning teams can benefit from technology platforms that aggregate data and automate analyses, helping unlock insights on the market landscape and clinical environment